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In connection with our interest in investigating novel rationally designed bitopic (i.e., 
orthosteric/allosteric) derivatives targeting muscarinic acetylcholine receptor (mAChR) subtypes 
(1,2,3), in this study we designed and synthesized a new set of ligands that integrate in the same 
molecular skeleton the pharmacophoric moieties of Xanomeline and of 77-LH-28-1 (1-[3-(4-butyl-
1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone). Xanomeline is a well-known M1/M4-
preferring orthosteric agonist, which ameliorated cognitive impairments in Alzheimer’s disease 
patients and showed activity in various models of schizophrenia, thus being potentially beneficial 
for treatment of positive, negative and cognitive symptoms (4). On the other hand, 77-LH-28-1 was 
characterized as an M1-selective, positive allosteric modulator, thus representing an interesting 
pharmacological tool with cognition enhancing properties (5). As illustrated below, we planned the 
novel bipharmacophoric derivatives as merged structures, with the tetrahydropyridine nucleus of 
Xanomeline as the central core. 
 
 
 
In the last years, different receptor sensors, based on the fluorescence resonance energy transfer 
(FRET), were generated for various G protein-coupled receptors, and represented a valuable tool to 
investigate real time receptor activation as well as ligand-receptor interactions. Recently, this 
analysis was performed also on a set of bitopic ligands designed for a selective interaction with M1 
mAChRs (6). Our preliminary results on the group of Xanomeline/77-LH-28-1 hybrid compounds 
indicate, for the M1 sensor, a reproducible activation response, which depends on the linker length. 
Conversely, no FRET-related effect could be detected at the M2 sensor. Thus, a critical spacer 
length of the hybrid compounds induces conformational changes with a degree of selectively for the 
M1 muscarinic receptor. The synthesis and the results of pharmacological investigation will be 
presented and discussed.    
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